ERR2598207
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_forebrain
- 7
- umap1_2d
- -4.057351516
- umap2_2d
- 2.048409084
- umap1_3d
- -2.910987797
- umap2_3d
- 2.877042703
- umap3_3d
- -2.053407943
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.670
- G2M_CHECKPOINT+0.670
- MYC_TARGETS_V1+0.510
- MYC_TARGETS_V2+0.510
- MITOTIC_SPINDLE+0.430
- WNT_BETA_CATENIN_SIGNALING+0.420
- DNA_REPAIR+0.340
- UNFOLDED_PROTEIN_RESPONSE+0.340
- NOTCH_SIGNALING+0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.260
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.390
- INTERFERON_ALPHA_RESPONSE-0.310
- ALLOGRAFT_REJECTION-0.260
- FATTY_ACID_METABOLISM-0.250
- INTERFERON_GAMMA_RESPONSE-0.210
- XENOBIOTIC_METABOLISM-0.200
- PEROXISOME-0.190
- MYOGENESIS-0.170
- ADIPOGENESIS-0.150
- KRAS_SIGNALING_DN-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598166 | fetal | fetal | 0.872 |
| 2 | ERR2598184 | fetal | fetal | 0.854 |
| 3 | ERR2598170 | fetal | fetal | 0.854 |
| 4 | ERR2598171 | fetal | fetal | 0.853 |
| 5 | SRR8613735 | — | E | 0.850 |
| 6 | ERR2598197 | fetal | fetal | 0.850 |
| 7 | ERR2598180 | fetal | fetal | 0.842 |
| 8 | ERR2598164 | fetal | fetal | 0.839 |
| 9 | ERR2598071 | fetal | fetal | 0.823 |
| 10 | MNG495 | — | — | 0.822 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.670 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.670 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.430 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.420 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.340 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.320 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.090 | Idelalisib | — uncovered |